The recent trend of population analysis for pediatric using allometric scaling and physiological sca

来源 :第五届定量药理学与新药评价国际会议 | 被引量 : 0次 | 上传用户:type
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  The pharmacokinetic(PK) of drugs and its parameters are different among pediatrics, children and adults due to physiological differences such as body size, maturation of organs.Since population pharmacokinetics modeling of adults is hard to be applied directly to pediatrics, the modified model for pediatric is required to explain the variability in pharmacokinetics of drug.The aim of this study is to review current trends and techniques of population pharmacokinetics studies in pediatrics and evaluate potential possibility of those methods as improved approaches for explanations of variability in pediatrics.In the recent, the allometric and physiological scaling method between covariates and maturation (e.g., age) based on population approaches have been appeared as a good alternative method for explanation of PK/PD in pediatrics.The most affected physiological condition to clearance and volume of distribution in pediatrics theoretically was body size which is involved in allometric scaling and maturations of organ functions depending on aging.Therefore, size functions and maturations functions put into population model additionally using allometric equation and sigmoid hyperbolic equations for explanations of change of organ maturations, respectively.It can improve the unexplained variability especially within 4 weeks of age and was also useful under 1 years of pediatrics in describing maturation process.In case of the pediatrics over 1 years old and children, population approaches with allometrics scaling alone, as size function, was suitable explained for above because those ages had similar organ functions in comparison with adults.Therefore, it is better to reflect on pediatric pharmacokinetics modeling using both methods than to use general population modeling for adults.In conclusion, covariate analyses and modeling of pediatric data result in optimization of drug for children with different ages, body weights.In further study, we will develop the pediatric PK model with every approach in several drug and will suggest best approach for pediatric.
其他文献
ObjectivesTo describe PK profiles of CPZ/SUL in HAP patients induced by multidrug-resistant (MDR) P.aeruginosa and Acinetobacter spp.To identify and quantify the covariate effects on the PK profile of
会议
Objective: To evaluate the safety and tolerance of multi-dose ulinastatin (UTI) for injection in Chinese healthy volunteers.Methods This is a parallel, randomized, double-blind, placebo-controlled, mu
Background: NAS is a set of physiologic signs of withdrawal resulting from opiate exposure, either in utero or as part of medical care.Although enteral morphine is used to treat NAS, the pharmacokinet
会议
Background: Hospital infections caused by Acinetobacter baumannii tend to be resistant to various antibiotics.Colistin is increasingly used worldwide as the last-line therapy against A.baumannii.The r
会议
Background and objectives: Bitopertin (RG1678, RO4917838) is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunction by increasing the synaptic concentration of glycine,
会议
Background: Breast cancer is one of the leading causes of mortality among women worldwide.As a potent multi-targeted receptor tyrosine kinase inhibitor, sunitinib has shown promising results in clinic
会议
Background and Purpose: The complex pharmacokinetic (PK) properties of monoclonal antibody (mAb) including a nonlinear pharmacokinetics and a significant individual variation in PK process can not be
Objective: The objective of this study is to develop population pharmacokinetics model of vancomycin in treatment of septicemia in infants under one year old, to investigate factors which have signifi
CPRCX is a novel investigated proton pump inhibitor, which shows dramatic success in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper f
会议
Background: Lung cancer is the most lethal form of cancer in the world.Sunitinib is a promising multi-targeted receptor tyrosine kinase (RTK) inhibitor with activity against vascular endothelial growt
会议